24th EDRN Steering Committee Meeting  
March 13-15, 2012  
Tempe Mission Palms Hotel & Conference Center  
Tempe, Arizona

Draft Agenda

Monday March 12, 2012

6:30 – 8:30 p.m.  Industry Forum

Tuesday March 13, 2012

7:00 – 8:00 a.m.  Sign-In and Continental Breakfast

8:00 – 8:05 a.m.  Welcome & Introduction  
Joshua LaBaer, M.D., Ph.D., Arizona State University

8:05 – 8:15 a.m.  Opening of Steering Committee Meeting  
Ian Thompson, M.D., University of Texas Health Sciences Center at San Antonio

8:15 – 8:40 a.m.  State of the EDRN  
Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:40 a.m. – 12:00 p.m.  Session 1: State of the Art in Proteomics
Chair: Daniel Liebler, Ph.D., Vanderbilt University School of Medicine  
NCI Program Liaison: Jacob Kagan, Ph.D.

8:40 – 9:05 a.m.  Quantitative Biology and Biomarker Discovery without Immunoassays  
Steven Carr, Ph.D., Broad Institute

9:05 – 9:15 a.m.  Q&A

9:15 – 9:40 a.m.  Tapping into Glycans for Biomarker Development: New Tools and Applications  
Brian Haab, Ph.D., Van Andel Research Institute

9:40 – 9:50 a.m.  Q&A

9:50 – 10:10 a.m.  Break
Tuesday March 13, 2012 Continued

Session 1: State of the Art in Proteomics Continued

10:10 – 10:35 a.m.  Unbiased Discovery of Serum Antibody Biomarkers
Thomas Kodadek, Ph.D., Scripps Research Institute

10:35 – 10:45 a.m.  Q&A

10:45 – 11:00 a.m.  SRM Analysis of Total and Free PSA in Blood
David Camp, Ph.D., Pacific Northwest National Laboratory

11:00 – 11:05 a.m.  Q&A

11:05 – 11:20 a.m.  Institutional Wisdom: Centralized Informatics for EDRN Comparative Proteomics
David Tabb, Ph.D., Vanderbilt Medical Center

11:20 – 11:25 a.m.  Q&A

11:25 a.m. – 12:00 p.m.  Panel Discussion led by session chair
Given the state of science in proteomics and glycomics, what are the most provocative questions the EDRN can address?

12:00 – 1:00 p.m.  Lunch (On Your Own)

1:00 – 3:15 p.m.  Session 2: State of the Art in Genomics
Chairs: Arul Chinnaian, M.D., Ph.D., University of Michigan
NCI Program Liaison: Lynn Sorbara, Ph.D.

1:00 – 1:25 p.m.  Deep Sequencing to Uncover Events Supporting Targeted Therapeutics in Individual Patients Diagnosed with Metastatic Triple Negative Breast Cancer
John Carpten, Ph.D., TGen

1:25–1:35 p.m.  Q&A
Tuesday March 13, 2012 Continued

Session 2: State of the Art in Genomics Continued

1:35 – 2:00 p.m. Circulating MicroRNA as Cancer Biomarkers: A Laboratory Medicine Perspective
Colin Pritchard, M.D., Ph.D., University of Washington

2:00 – 2:10 p.m. Q&A

2:10 – 2:35 p.m. Confidence in Results from State of the Art Genomics Measurements
Marc Salit, Ph.D., National Institute of Standards and Technology

2:35 – 2:45 p.m. Q&A

2:45 – 3:15 p.m. Panel Discussion led by session chair
Given the state of science in genomics, what are the most provocative questions the EDRN can address?

3:15 – 3:35 p.m. Break

3:35 – 5:50 p.m. Session 3: Integrating Imaging and Biomarkers
Chair: Hemant Roy, M.D., NorthShore University HealthSystem
NCI Program Liaison: Richard Mazurchuk, Ph.D.

3:35 – 4:00 p.m. Probing Tissue Heterogeneity with Multiplex in situ Analysis of Cells and Pathways in Epithelial Tissue
Michael Gerdes, Ph.D., GE Global Research

4:00 – 4:10 p.m. Q&A

4:10 – 4:35 p.m. Clinical Trials of Novel Imaging Biomarkers in ACRIN: Current Status and Future Directions
David Mankoff, M.D., Ph.D., University of Washington

4:35 – 4:45 p.m. Q&A
Tuesday March 13, 2012 Continued

Session 3: Integrating Imaging and Biomarkers Continued

4:45 – 5:10 p.m.  Physiological and Metabolic MR Markers for Characterizing Patients with Cancer
Sarah Nelson, Ph.D., University of California, San Francisco

5:10 – 5:20 p.m.  Q&A

5:20 – 5:50 p.m.  Panel Discussion led by session chair
What are the most provocative questions the EDRN can address on integrating imaging and biomarkers?

5:50 p.m.  Adjourn for the day

Wednesday March 14, 2012

7:00 – 8:00 a.m.  Sign-In and Continental Breakfast

8:00 a.m. – 12:00 p.m.  Collaborative Group Meetings
Breast and Gynecological Cancers
Gastrointestinal Cancers
Lung and Upper Aerodigestive Cancers
Prostate and Urological Cancers

10:00 – 10:20 a.m.  Break

12:00 – 1:30 p.m.  Lunch (On Your Own)

12:00 – 1:30 p.m.  EDRN EC Meeting (Closed Session)

1:30 – 3:30 p.m.  Breakout Sessions to Discuss Provocative Questions
There will be three groups and each will discuss questions related to proteomics, genomics and imaging identified during Monday’s Scientific Sessions. EDRN PIs will be assigned to a specific group so that there are PIs from each collaborative group in each discussion group.
Wednesday March 14, 2012

Breakout Sessions to Discuss Provocative Questions Continued

- Discussion Leader Group 1: Sam Hanash, M.D., Ph.D., Fred Hutchinson Cancer Research Center
- Discussion Leader Group 2: David Sidransky, M.D., Johns Hopkins University School of Medicine
- Discussion Leader Group 3: Sanjiv Gambhir, M.D., Ph.D., Stanford University

3:30 – 3:50 p.m.      Break

3:50 – 5:50 p.m.      Interest Group Meetings

Imaging
- Chair: James Brooks M.D., Stanford University
- NCI Liaison: Richard Mazurchuk, Ph.D.

Biomarker Reference Laboratories
- Chair: Daniel Chan, Ph.D., Johns Hopkins University
- NCI Liaison: Lynn Sorbara, Ph.D.

Thursday, March 15, 2012

7:00 – 8:00 a.m.      Sign-In and Continental Breakfast

Closed Session EDRN PIs and Co-PIs only

8:00 – 8:20 a.m.      Report on Network Consulting Team Meeting
Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:20 – 9:05 a.m.      Outcome of Provocative Questions Discussions
Presentations by three discussion group leaders (15 minutes each)

9:05 – 9:15 a.m.      Report from Advocates
Thursday, March 15, 2012 Continued

9:15 – 9:30 a.m.  Report from Industry Forum
Craig Tuttle, M.S., M.B.A., Transgenomic, Inc.

9:30 – 10:00 a.m.  Outcome of PCA-3 Validation Trial
John Wei, M.D., University of Michigan

10:00 – 10:20 a.m.  Break

10:20 – 11:50 a.m.  Team Projects Updates (15 minutes each)
- Prostate
- Breast
- Ovarian
- Lung
- Pancreas
- Colon

11:50 a.m. – 12:20 p.m.  Reports from Interest Groups (10 minutes each)
- BRLs
- Imaging

12:20 – 12:30 p.m.  Final Remarks
- Ian Thompson, M.D., University of Texas Health Sciences Center at San Antonio
- Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

12:30 p.m.  Adjourn